Abstract:Schematic diagram showing the process of the Delphi method for achieving the final 29 consensus statements for Palforzia®‐based peanut‐immunotherapy in the United Kingdom. Background Palforzia® enables the safe and effective desensitisation of children with peanut allergy. The treatment pathway requires multiple visits for dose escalation, up‐dosing, monitoring of patients taking maintenance therapy and conversion onto daily real‐world peanut consumption. The demand for peanut immunotherapy outstrips current National Health Service (NHS) capacity and requires services to develop a national consensus on how best to offer Palforzia® in a safe and equitable manner. We undertook a Delphi consensus exercise to determine guidance statements for the implementation of Palforzia®‐based immunotherapy in the NHS. Methods We undertook focus groups with children and young people who had received peanut immunotherapy to assess what was important for them and their carers. Common themes from patients formed the basis of creating draft statements. A panel of 18 multi‐disciplinary professionals engaged in two rounds of anonymised voting to adapt the statements and score their importance. A final consensus workshop consolidated any variation in comments and scores to develop the final guidance statements. Results The panel achieved consensus on 91% (29/32) of guidance statements, demonstrating strong consensus around pragmatic principles for assuring the integrity of consent, safety and conversion from Palforzia® to real‐world peanut products. The greatest amount of feedback was generated from three broad issues; (i) whether eligibility assessment should include compulsory peanut challenges and whether these should be designed to assess the threshold at which patients react to peanut, (ii) the governance processes to best ensure that patients' interests are prioritised and (iii) how to safely transition young people to other services, or discharge them, while they are taking daily peanut. Conclusions This consensus highlights the urgent need for the NHS to increase capacity for undertaking diagnostic food challenges as well as developing Palforzia® immunotherapy pathways. The voting panel agreed that families of peanut allergic children should be made aware of immunotherapy, that eligibility assessment should include how co‐morbid conditions are managed and that services should monitor for adverse effects. The finalised statements are now published online for clinical practice in the UK. These guidance statements will be adapted in the coming years as more evidence is published and as the international experience of peanut immunotherapy evolves.

Exploratory immunogenicity outcomes of peanut oral immunotherapy: Findings from the PALISADE trial

The Risk Reduction of Accidental Exposure-Related Systemic Allergic Reactions Extrapolated Based on Food Challenge Data After 1 Year of Peanut Oral Immunotherapy

PSY2 THE ESTIMATED RISK REDUCTION OF ANAPHYLACTIC REACTIONS ASSOCIATED WITH AR101 ORAL IMMUNOTHERAPY FOLLOWING ACCIDENTAL PEANUT EXPOSURE: AN ANALYSIS BASED ON CLINICAL TRIAL DATA

Peanut-specific IgG subclasses as biomarkers of peanut allergy in LEAP study participants

Neutralizing IgG4 antibodies are a biomarker of sustained efficacy after peanut oral immunotherapy

From Skin to Solution: Exploring Epicutaneous Immunotherapy for Peanut Allergy—A Systematic Review and Meta-Analysis

Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy

Early Peanut Immunotherapy in Children (EPIC) trial: protocol for a pragmatic randomised controlled trial of peanut oral immunotherapy in children under 5 years of age

Does clinical outcome of birch pollen immunotherapy relate to induction of blocking antibodies preventing IgE from allergen binding? A pilot study monitoring responses during first year of AIT

Preclinical efficacy of peanut-specific IgG4 antibody therapeutic IGNX001

Interaction Between Baseline Participant Factors and Treatment Effects Following Peanut Oral Immunotherapy

Peanut allergy: risk factors, immune mechanisms, and best practices for oral immunotherapy success

Peanut allergen characterization and allergenicity throughout development

Safety and adherence of early oral immunotherapy for peanut allergy in a primary care setting: a retrospective cross-sectional study

Serologic Measurements for Peanut Allergy: Predicting Clinical Severity is Complex

Efficacy of Allergen-Specific Immunotherapy for Peanut Allergy: a Meta-Analysis of Randomized Controlled Trials.

Peanut Immunotherapy Increases Allergic and Anaphylactic Reactions, Finds Review

BSACI guidance for the implementation of Palforzia® peanut oral immunotherapy in the United Kingdom: A Delphi consensus study

Effect of Avoidance on Peanut Allergy after Early Peanut Consumption

Peanut Oral Immunotherapy: a Current Perspective

Is Component-Specific Antibody Testing Sufficient to Replace the Oral Food Challenge in the Diagnostics of Peanut-Sensitized Children? A Proof-of-Concept Study